Evaluation of Diet and Exercise in Prostate Cancer Patients (CRONOS II)

AbbVie

Status: Completed

Conditions: Prostate Cancer

Study type: Observational

Funder types: Industry; Other

Identifiers

NCT01960881

P14-096

Details and patient eligibility

About

Canadian Real Life Evaluation of the Effect of Diet and Exercise in Prostate Cancer Patients Managed with Lupron.

Full description

This is a study utilizing a prospective cohort design. Patients with Prostrate cancer (PCa) who are prescribed Lupron will be entered into the study cohort and will be followed for a maximum of 18 months with recommended assessments at 3, 6, 12 and 18 months after Day 1. Treatment of the patients and follow up will be according to the physicians' judgment, regional regulations and the product monograph.

Enrollment: 1,331 patients

Sex

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

i. Adult ≥ 18 years old

ii. Has provided written informed consent allowing the use of their data for the study and providing permission for contact by the study personnel.

iii. Diagnosed with PCa.

iv. Prescribed Lupron as part of his treatment by his treating physician.

Exclusion criteria

i. Patient cannot or will not sign informed consent.

ii. Presence of other condition that, in the opinion of the treating physician, prohibits the patient from participating in the study or obscures the assessment of the treatment of PCa.

iii. More than 6 months of therapy if currently on continuous Luteinizing hormone-releasing hormone (LHRH) treatment.

iv. If at study enrollment the intent is to only prescribe 1 dose of Lupron (leuprolide acetate)

Trial design

1,331 participants in 1 patient group

Prostate Cancer Patients

Description:

Prostate Cancer Patients